Physician profile
Amber Marie Kellerman
NPI 1689292997
$5,058.68
in general payments reported to CMS, 2019-2025
29 companies · $1,324 in 2025
The $1,324 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $516 · 2022: $927 · 2023: $1,131 · 2024: $1,161 · 2025: $1,324.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,616.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,616.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $946.38 | 2021-2025 | |
| Lilly USA, LLC | $598.01 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $580.22 | 2021-2025 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $517.21 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Novartis Pharmaceuticals Corporation | $472.93 | 2021-2025 | |
| Pfizer INC. | $277.70 | 2022-2025 | |
| Amgen INC. | $224.69 | 2022-2024 | Prolia, Evenity |
| Mylan Specialty L.P. | $212.76 | 2021-2024 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $190.81 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Sumitomo Pharma America, INC. | $176.09 | 2023-2025 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $124.32 | 2021-2025 | |
| Dexcom, INC. | $101.68 | 2022-2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $87.40 | 2021-2024 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $69.53 | 2021-2023 | Abilify Maintena, Rexulti |
| Janssen Pharmaceuticals, INC | $68.66 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $64.01 | 2025 | Fanapt |
| Viatris Specialty LLC | $50.95 | 2025 | Yupelri |
| Amarin Pharma, INC. | $41.10 | 2021 | |
| Glaxosmithkline, LLC. | $40.08 | 2022-2025 | Trelegy Ellipta |
| Biohaven Pharmaceutical Holding Company LTD. | $33.30 | 2022 | |
| Eisai INC. | $31.41 | 2021 | |
| Grifols USA, LLC | $29.62 | 2023-2025 | Prolastin-C Liquid |
| Axsome Therapeutics, INC. | $23.79 | 2024 | Auvelity |
| Merck Sharp & Dohme LLC | $18.31 | 2022 | |
| Phathom Pharmaceuticals, INC. | $18.04 | 2025 | Voquezna |
| Seqirus USA INC | $16.72 | 2024 | Flucelvax, Fluad |
| Exact Sciences Corporation | $15.46 | 2025 | Cologuard Collection Kit |
| Aimmune Therapeutics, INC. | $14.23 | 2024 | |
| Electromed, INC. | $13.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Kellerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.